Infectious Diseases Trend Monitor: China

Monitor the infectious diseases IVD landscape in China

China’s government is building up the country’s in vitro diagnostics (IVD) testing capacity to strengthen the country’s response to infectious diseases. The government is expected to invest more than Rmb 15.6bn in 2023 on infectious diseases prevention and control, targeting diseases including HIV, tuberculosis and other severe infectious diseases such as covid-19.

Clearstate’s Infectious Diseases Trend Monitor report on China helps businesses understand local infectious disease dynamics and how it impacts testing.

Learn more

Why Infectious Diseases Trend Monitor

Track key developments 

Understand China’s infectious disease testing landscape and how regulations, new products and technology developments are impacting  test volume and infectious disease diagnostics market size, giving you timely updates on the rules of the game for your commercial team to react quickly.

Identify competition to stay ahead

Know how top IVD companies are performing in the market, average selling prices and the market shares of international versus domestic companies , giving you the insights on which are the closest competition and how to win them.

Anticipate opportunities

Strengthen response to shifting disease trends and meet future demand for testing with comprehensive data and analysis on emerging and endemic infections from covid-19 to hepatitis, which provide you insights on whitespaces for future revenue growth.

What’s covered?

The China Infectious Diseases Trend Monitor report provides detailed information on trends in infectious diseases and the IVD market:

  • Epidemiological trends 
  • Policy trends and impact on infectious disease testing
  • Testing landscape across patient journey in screening, diagnosis, treatment and management
  • Reimbursement landscape
  • Test volumes by disease type and stage in the patient journey
  • Market size and 5-year CAGR forecast by technology (centralised, molecular, point-of-care and tissue diagnostics)
  • Competitive landscape with international v domestic market share, average selling price of top companies

Infectious diseases tracked include:

  • Respiratory Tract Infections (RTIs)
    • Influenza
    • Covid-19
    • Other RTIs (RSV, Adenovirus, Bordetella)
  • Virology
    • Hepatitis (HBV, HCV)
    • HPV
    • HIV
  • Sexually Transmitted Infections (STIs)
    • Chlamydia (CT/NG)
    • Other STIs
  • Bacteriology 
    • Tuberculosis
    • Hospital-acquired infections
  • Vector-borne diseases 
    • Malaria
    • Dengue

Key companies covered include:

  • Abbott
  • Roche
  • Da An
  • Wondfo
  • Autobio
  • Xinchuang
  • Sansure
  • Liferiver

Enquire

To learn more about access and pricing to Clearstate’s Infectious Disease Trend Monitor, please fill out the form below.